[1]赵立伟,李 芳.替罗非班联合丁苯酞治疗进展性脑卒中对患者P-selectin、CD63、CD62p水平及预后的影响[J].陕西医学杂志,2021,50(1):89-92.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.024]
　ZHAO Liwei,LI Fang.Effect of tirofiban combined with butylphthalide on the levels of P-selectin,CD63,CD62p and prognosis in patients with progressive stroke[J].,2021,50(1):89-92.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.024]
点击复制

替罗非班联合丁苯酞治疗进展性脑卒中对患者P-selectin、CD63、CD62p水平及预后的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年1期
页码:
89-92
栏目:
药物与临床
出版日期:
2021-01-05

文章信息/Info

Title:
Effect of tirofiban combined with butylphthalide on the levels of P-selectin,CD63,CD62p and prognosis in patients with progressive stroke
作者:
赵立伟1; 2; 李 芳1
(1.锦州医科大学附属第一院神经内科,辽宁 锦州 121000; 2.辽宁省鞍山市长大医院神经内科,辽宁 鞍山114000)
Author(s):
ZHAO Liwei; LI Fang
(Department of Neurology,the First Affiliated Hospital of Jinzhou Medical University,Jinzhou 121000,China)
关键词:
脑卒中;  替罗非班;  丁苯酞;  P-选择素;  溶酶体膜糖蛋白;  α颗粒膜糖蛋白
Keywords:
Stroke;  Tirofiban;  Butylphthalide;  P-selectin;  Lysosome intact membrane protein;  α-Granulemembrane protein
分类号:
R 743.3
DOI:
DOI:10.3969/j.issn.1000-7377.2021.01.024
文献标志码:
A
摘要:
目的:探讨替罗非班联合丁苯酞治疗进展性脑卒中对患者P-选择素(P-selectin)溶酶体膜糖蛋白(CD63)、α颗粒膜糖蛋白(CD62p)水平及预后的影响。方法:选取108例进展性脑卒中患者,随机将其分为治疗组(n=54)和对照组(n=54),对照组给予丁苯酞氯化钠注射液进行治疗,疗程14 d,14 d后给予丁苯酞软胶囊进行治疗; 治疗组在对照组的基础上给予盐酸替罗非班氯化钠注射液进行治疗,两组均治疗28 d。比较两组治疗28 d后的临床疗效,对比两组治疗前、治疗14、28 d后的神经功能缺损程度,比较两组治疗前、治疗28 d后的炎症因子及血小板活化标志物水平,统计两组治疗期间的不良反应发生率。结果:两组总有效率比较,治疗组高于对照组(92.59%与75.93%,P<0.05)。与治疗前比较,治疗14、28 d后,两组NIHSS评分均呈逐渐降低趋势,且治疗组均低于对照组(P<0.05)。与治疗前比较,治疗28 d后,两组血清白介素-6(IL-6)、高敏C反应蛋白(hs-CRP)、P-selectin、CD63、CD62p水平均降低,且治疗组均低于对照组(P<0.05)。两组治疗期间的不良反应发生率比较差异无统计学意义(7.41%与 12.96%, P>0.05)。结论: 替罗非班联合丁苯酞治疗进展性脑卒中可明显降低患者血清P-selectin、CD63、CD62p水平,抑制血栓形成,同时可减轻机体炎症反应,进而有助于改善神经功能及预后,提高疗效,且安全性良好。
Abstract:
Objective:To investigate the effect of tirofiban combined with butylphthalide on the levels of P-selectin,lysosome intact membrane protein(CD63),α-granulemembrane protein(CD62p)and prognosis in patients with progressive stroke.Methods:108 patients with progressive stroke were selected and divided into the treatment group(n=54)and the control group(n=54)randomly.The control group was treated with butylphthalide sodium chloride injection for treatment,and the course of treatment was 14 days,and they were treated with butylphthalide soft capsules after 14 days.The observation group was treated with tirofiban hydrochloride sodium chloride injection on the basis of the control group.Both groups were treated for 28 days.The clinical efficacy in the two groups after 28 days of treatment was compared.The neurological deficits between the two groups before and after 14 and 28 days of treatment was compared.The inflammatory factors and platelet activation markers levels in the two groups before and after 28 days of treatment were compared.The incidence of adverse reactions during the treatment in the two groups was counted.Results:Comparing the total effective rate between the two groups,the treatment group was higher than the control group(92.59% vs.75.93%,P<0.05).Compared with before treatment,after 14 and 28 days of treatment,the scores of NIHSS in the two groups showed a gradual decrease trend,and the treatment group was lower than the control group(P<0.05).Compared with before treatment,after 28 days of treatment,the levels of serum IL-6,hs-CRP,P-selectin,CD63,and CD62p in the two groups decreased,and the treatment group was lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period(7.41% vs.12.96%,P>0.05).Conclusion:Tirofiban combined with butylphthalide in the treatment of progressive stroke can significantly reduce the levels of serum P-selectin,CD63,and CD62p in patients,inhibit thrombosis,and reduce the body's inflammation,thereby helping to improve nerve function and prognosis,improve efficacy,and with higher safety.

参考文献/References:

[1] 陈胜云,王丹丹,杨中华,等.静脉应用阿替普酶在急性缺血性卒中治疗中的应用[J].中国卒中杂志,2016,11(10):821-823.
[2] Muchada M,Rubiera M,Rodriguez-Luna D,et al.Baseline national institutes of health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke[J].Stroke,2018,45(4):1059-1063.
[3] Liu J,Shi Q,Sun Y,et al.Efficacy of tirofibanadministered at different time points afterintravenous thrombolytic therapy with alteplasein patients with acute ischemic stroke[J].J Stroke Cerebrovasc Dis,2019,28(4):1126-1132.
[4] 俞小梅,王喜丰,张 静,等.丁苯酞注射液及丁苯酞胶囊治疗急性脑梗死患者的临床疗效对比[J].实用医学杂志,2016,32(17):2921-2924.
[5] 钟士红,范文辉,李 浩.替罗非班在急性脑梗死溶栓后再闭塞中的治疗价值及对vWF、sCD40L、NIHSS评分等的影响[J].中国医院药学杂志,2020,1(3):1-5.
[6] 中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组.急性缺血性卒中血管内治疗中国指南(2018)[J].中国卒中杂志,2018,13(7):706-729.
[7] 林 菁,周经霞,陈 聪,等.依达拉奉联合氟哌噻吨美利曲辛治疗脑卒中临床研究[J].中国药业,2020,29(14):83-86.
[8] 张 竹,李东仕,刘新通.动脉内灌注替罗非班治疗进展性缺血性脑卒中的疗效及安全性[J].中国现代药物应用,2020,14(7):97-99.
[9] 许 璇,余 科,曾洁芳,等.替罗非班联合丁苯酞治疗进展性脑梗死的疗效分析[J].广州医药,2019,50(1):76-79.
[10] 李耀鹏,赵 鑫,朱晓临.替罗非班治疗缺血性脑卒中的应用进展[J].卒中与神经疾病,2020,27(1):127-132.
[11] 王 瑞,屈 征,张明睿,等.替罗非班对预防小卒中静脉溶栓后血管再闭塞的研究[J].广东医学,2019,40(7):1001-1004.
[12] 张立芳,李 博.丁苯酞联合替罗非班治疗进展性脑卒中的临床疗效及对血小板的影响[J].广西医科大学学报,2019,36(3):399-403.
[13] 张育德,冯翠玲,白树风.替罗非班联合奥扎格雷钠治疗进展性脑卒中的临床疗效及对血小板功能的影响[J].中国医院药学杂志,2015,35(14):1306-1309.
[14] 焦冬生,赵 全,钱时德,等.替罗非班联合奥扎格雷纳治疗进展性脑卒中的临床疗效及其对血小板水平影响分析[J].贵州医药,2018,42(1):39-41.
[15] 刘深龙,辛立建,马媛媛,等.替罗非班在进展性脑梗死治疗中的应用效果及对患者血清炎性因子、血小板功能的影响[J].山东医药,2019,59(17):44-46.

相似文献/References:

[1]胡 平,张裕民.两种内固定术在老年脑卒中偏瘫侧股骨粗隆间骨折治疗中的运用效果观察[J].陕西医学杂志,2019,(3):355.
[2]张晓春,李佳良,李 婷.脑卒中后焦虑相关因素分析[J].陕西医学杂志,2020,49(2):180.
　ZHANG Xiaochun,LI Jialiang,LI Ting..Research on related factors of poststroke anxiety[J].,2020,49(1):180.
[3]翟向伟,高宏勇△,王燕妮,等.冻干重组人脑利钠肽联合替罗非班对急性心肌梗死患者趋化素、半凝乳素-3水平的影响*[J].陕西医学杂志,2020,49(8):995.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.021]
　ZHAI Xiangwei,GAO Hongyong,WANG Yanni,et al.Effect of lyophilized recombinant human brain natriuretic peptide combined with tirofiban on the levels of chemorin and Gal-3 in patients with acute myocardial infarction[J].,2020,49(1):995.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.021]
[4]陈 芳,孙黎博△.瑞舒伐他汀与替罗非班联合冠脉介入治疗急性心肌梗死疗效及对患者心功能、循环内皮祖细胞数量的影响*[J].陕西医学杂志,2020,49(10):1244.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.011]
　CHEN Fang,SUN Libo..Effect of rosuvastatin and tirofiban combined with PCI in treatment of patients with acute myocardial infarction and its influence on cardiac function and the number of circulating endothelial progenitor cells[J].,2020,49(1):1244.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.011]
[5]黄四春,张忠胜,余炳坚,等.非大脑中动脉狭窄的单发豆纹动脉梗塞发生早期神经功能恶化危险因素探讨及风险列线图模型建立[J].陕西医学杂志,2022,51(7):823.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.013]
　HUANG Sichun,ZHANG Zhongsheng,YU Bingjian,et al.Risk factors of early neurological function deterioration in single lenticulostriate artery infarction patients without middle cerebral artery stenosis and the establishment of risk nomogram model[J].,2022,51(1):823.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.013]
[6]陈 光,付 淼.急性缺血性脑卒中患者脑血管储备功能与其急诊治疗结局相关性分析[J].陕西医学杂志,2023,52(1):53.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.012]
[7]朱钦辉,陈丹霞,魏统国.替罗非班联合直接取栓对急诊急性脑梗死患者血管再通率影响的临床研究[J].陕西医学杂志,2024,(1):95.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.021]
　ZHU Qinhui,CHEN Danxia,WEI Tongguo.Effect of direct thrombectomy combined with tirofiban on rate of vascular revascularization in emergency patients with acute cerebral infarction[J].,2024,(1):95.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.021]

更新日期/Last Update: 2021-01-05